About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 96 record(s)
Req # A-2021-001858
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_04410444, E2B_04463498, E2B_04376583, E2B_04374064, E2B_04374064, E2B_04358912, E2B_04490526, 000965008, E2B_04413796, E2B_04478547, E2B_04413148, E2B_04428806, E2B_04461350, E2B_04412524, E2B_04466954, E2B_04434455, E2B_04433543, E2B_04302486.Organization: Health Canada
April 2022
Req # A-2021-001861
Adverse Drug Reaction (ADR). Report number: E2B_04286172.Organization: Health Canada
April 2022
Req # A-2021-001865
Adverse Drug Reactions (ADRs). Report numbers: 000525134, E2B_01251264, E2B_01251307.Organization: Health Canada
April 2022
Req # A-2021-001874
Adverse Drug Reactions (ADRs) for Leflunomide. Report numbers: 000967604, 000968020.Organization: Health Canada
April 2022
Req # A-2021-001882
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-119213-431.Organization: Health Canada
April 2022
Req # A-2021-001890
Adverse Drug Reactions (ADRs). Report numbers: E2B_04712176, E2B_04715481, E2B_03710772, E2B_04384481, E2B_04623323, E2B_04694587, E2B_03438771, E2B_04661609, 000966181, 000967679, 000968801, 000969004, 000969684, 000969690, E2B_03798876, 000970266, 000970375, 000970378, 000970478, 000971454.Organization: Health Canada
April 2022
Req # A-2021-001895
Adverse Drug Reaction (ADR). Report number: E2B_01845267.Organization: Health Canada
April 2022
Req # A-2021-001903
Adverse Drug Reactions (ADRs). Report numbers: 000714744, 000722369, 000602607, 000606771, 000567392.Organization: Health Canada
April 2022
Req # A-2021-001904
Adverse Drug Reaction (ADR). Report Number: E2B_01440424.Organization: Health Canada
April 2022
Req # A-2021-001952
Adverse Drug Reactions (ADRs). Report Numbers: E2B_04738297, E2B_04775138, E2B_04782560, E2B_04785424.Organization: Health Canada
April 2022